Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
J Randolph HechtSara LonardiJohanna BendellHao-Wen SimTeresa MacarullaCharles D LopezEric Van CutsemAndrés Muñoz MartinJoon Oh ParkRichard GreilHong WangRebecca R HozakIvelina GueorguievaYong LinSujata RaoBaek-Yeol RyooPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
PEG added to FOLFOX did not improve efficacy in advanced gemcitabine-refractory PDAC. Safety findings were consistent as previously observed from PEG with chemotherapy; toxicity was manageable and tolerable. Exploratory pharmacodynamic results were consistent with immunostimulatory signals of the IL-10R pathway.